Institute Paoli-Calmettes-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2023

  1. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

2022

  1. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10

  2. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    European Urology, Vol. 82, Núm. 2, pp. 212-222

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

  2. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

  3. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1

  4. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

  5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

  6. The LACC Trial and Minimally Invasive Surgery in Cervical Cancer

    Journal of Minimally Invasive Gynecology

2019

  1. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    Nature Medicine, Vol. 25, Núm. 11, pp. 1706-1714

  2. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 3, pp. 522-528

  3. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: A study of behalf of the infectious diseases and acute leukemia working parties of the EBMT

    Bone Marrow Transplantation, Vol. 53, Núm. 4, pp. 422-430

  2. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  3. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2017

  1. Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

    European Journal of Cancer

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

    European Journal of Cancer, Vol. 76, pp. 36-44

  4. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant

    Haematologica, Vol. 102, Núm. 2, pp. 401-410